Table 2.
Multivariate analysis on SSI.
| Variable | N | Event N | OR1 | 95% CI1 | p-value |
|---|---|---|---|---|---|
| AP regimen | |||||
| Cefuroxim/metronidazole | 226 | 13 | – | – | |
| Mezlocillin/sulbactam | 191 | 3 | 0.22 | 0.07–0.70 | 0.010 |
| Tazobactam/piperacillin | 114 | 3 | 0.43 | 0.14–1.36 | 0.10 |
| Sex | |||||
| Male | 306 | 7 | – | – | |
| Female | 225 | 12 | 2.42 | 1.02–5.75 | 0.045 |
| Age | 531 | 19 | 0.97 | 0.93–1.01 | 0.19 |
| ASA-status | |||||
| I | 94 | 1 | – | – | |
| II | 253 | 7 | 3.79 | 0.72–20.1 | 0.12 |
| III | 184 | 11 | 8.6 | 1.59–46.5 | 0.012 |
| Diagnosis | |||||
| Colon carcinoma | 325 | 10 | – | – | |
| Rectum carcinoma | 204 | 9 | 1.67 | 0.69–4.01 | 0.25 |
| Colon and rectum carcinoma | 2 | 0 | 12.4 | 0.26–596 | 0.20 |
| Perioperative AP timing | |||||
| < 30 min | 326 | 10 | – | – | |
| 30–60 min | 166 | 8 | 1.42 | 0.58–3.46 | 0.45 |
| > 60 min | 22 | 1 | 2.33 | 0.35–15.4 | 0.38 |
| After incision | 15 | 0 | 0.85 | 0.04–16.0 | 0.91 |
| Not stated | 2 | 0 | 20.7 | 0.47–1.05 | 0.13 |
| Null deviance | 164 | ||||
| Null distribution | 530 | ||||
| Log-likelihood | − 73.1 | ||||
| Akaike Information Criterion | 172 | ||||
| Bayesian information criterion | 228 | ||||
| Deviance | 146 | ||||
| Residual df | 518 | ||||
| No. observation | 531 | ||||
1OR, Odds Ratio.
AP, Antimicrobial prophylaxis; ASA-Status American Society of Anesthesiology; BMI, Body mass index; CI, Confidence interval; SSI, Surgical site infection. Significant values are in bold.